作者
Apurva Jain, Mitesh J Borad, Robin Kate Kelley, Ying Wang, Reham Abdel-Wahab, Funda Meric-Bernstam, Keith A Baggerly, Ahmed Omar Kaseb, Humaid O Al-Shamsi, Daniel H Ahn, Thomas DeLeon, Andrea Grace Bocobo, Tanios Bekaii-Saab, Rachna T Shroff, Milind Javle
发表日期
2018/1
期刊
JCO Precision Oncology
卷号
2
页码范围
1-12
出版商
American Society of Clinical Oncology
简介
Purpose
FGFR genetic aberrations (GAs) occur in an estimated 10% to 16% of intrahepatic cholangiocarcinomas (CCAs). The natural history of CCA with FGFR GAs, the prognostic role of coexisting GAs, and the outcome with FGFR-targeted inhibitors are unknown.
Patients and Methods
Patients with CCA with FGFR GAs were identified using next-generation sequencing or fluorescence in situ hybridization from four tertiary cancer centers and compared with FGFR wild-type counterparts. Data reviewed included demographic, treatment, overall survival (OS), and GA data. Fisher’s exact test, Kaplan-Meier plots, and log-rank tests were used for statistical analysis.
Results
Three hundred seventy-seven patients with CCA were identified, and 95 had FGFR GAs. FGFR2 GA was most common (n = 74, with 63 fusions) and seen in intrahepatic CCA. In patients with CCA, FGFR GAs occurred more frequently in younger …
学术搜索中的文章
A Jain, MJ Borad, RK Kelley, Y Wang, R Abdel-Wahab… - JCO Precision Oncology, 2018